---
layout: default
title: Ganirelix
parent: 僅模型預測 (L5)
nav_order: 745
evidence_level: L5
indication_count: 10
---

# Ganirelix
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ganirelix: From Undetermined Original Indication to Hypertrichosis

## One-Sentence Summary

Ganirelix (DrugBank DB06785) is a GnRH (gonadotropin-releasing hormone) antagonist; its original approved indication is not captured in this evidence pack, and its detailed mechanism of action is also flagged as a data gap. The TxGNN model's top prediction is **Hypertrichosis (disease)**, with a very high similarity score but **zero clinical trials and zero literature** currently supporting this specific link.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no licenses or indication records on file in this data pack |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (flagged as data gap DG002). Based on the mechanistic-link notes the model itself generated across this drug's candidate list, ganirelix is consistently described as a GnRH antagonist that suppresses pituitary LH/FSH secretion — this is the drug's known pharmacological class, even though a formal MOA record was not retrieved here.

For the top-ranked candidate, hypertrichosis (excess hair growth), the system's own rationale explicitly states there is **no known mechanistic connection** between GnRH/LH-FSH suppression and hair-follicle growth regulation, and that the prediction carries **no supporting clinical or literature data**. In other words, the high TxGNN similarity score reflects a graph-embedding pattern, not a validated pharmacological hypothesis.

It's also worth noting that rank 3 in this same batch ("malformation syndrome with odontal/periodontal component") returned 20 literature hits, but manual review found all 20 to be generic periodontology papers with no mention of ganirelix or GnRH pathways — a likely keyword/embedding false-positive. This is a signal that this batch of predictions, as a whole, needs cautious interpretation rather than face-value trust in high similarity scores.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## US Market Information

No marketing authorization (NDA/license) records are available in this data pack — `market_status` is recorded as "未上市" (not marketed) with 0 total licenses on file.

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data were all queried but not found in this data pack — DG001, TFDA label warnings, is flagged as a Blocking-severity gap.)

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked candidate indication (hypertrichosis) has no clinical trials, no literature, and no plausible mechanistic link per the model's own assessment — this is a pure L5 model-prediction-only signal at decision stage S0. Combined with two unresolved drug-level data gaps (missing regulatory safety label and missing MOA), this candidate cannot advance past initial screening.

**To proceed, the following is needed:**
- TFDA/FDA package insert (warnings, contraindications) — currently Blocking (DG001)
- Confirmed mechanism of action from DrugBank API — currently High severity (DG002)
- Original approved indication and regulatory license records for ganirelix, which are entirely absent from this pack
- Independent expert review of whether any GnRH-antagonist-to-hypertrichosis mechanistic hypothesis is biologically plausible, since none is currently supported by data
- If further candidates from this batch are pursued (e.g., precocious puberty entries, which are at least endocrinologically adjacent to GnRH pathways), re-run evidence collection specifically for those, since the current top-ranked candidate is not the most mechanistically coherent option in the list
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

